Biogen (BIIB) is a publicly traded Healthcare sector company. As of May 20, 2026, BIIB trades at $187.75 with a market cap of $28.33B and a P/E ratio of 20.20. BIIB moved -1.35% today. Year to date, BIIB is +7.54%; over the trailing twelve months it is +43.85%. Its 52-week range spans $110.04 to $205.97. Analyst consensus is buy with an average price target of $218.76. Rallies surfaces BIIB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Biogen Acquires Apellis for $5.3B and Advances Tau Drug, Shares Jump 10%: Biogen completed its $5.3B acquisition of Apellis Pharmaceuticals, adding marketed drugs SYFOVRE and EMPAVELI that generated $689M in 2025 and featuring $4.00-per-share CVRs tied to SYFOVRE revenue milestones. The company also advanced tau-targeting Alzheimer’s drug diranersen to late-stage trials after mid-stage data showed slowed disease progression, sending shares up 10%.
| Metric | Value |
|---|---|
| Price | $187.75 |
| Market Cap | $28.33B |
| P/E Ratio | 20.20 |
| EPS | $9.35 |
| Dividend Yield | 0.00% |
| 52-Week High | $205.97 |
| 52-Week Low | $110.04 |
| Volume | 668.76K |
| Avg Volume | 0 |
| Revenue (TTM) | $9.94B |
| Net Income | $1.37B |
| Gross Margin | 75.49% |
26 analysts cover BIIB: 0 strong buy, 15 buy, 10 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $218.76.